PCN77 Cost-effectiveness analysis of adjuvant FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for resected pancreatic cancer in the United States: based on PRODIGE and APACT trial
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.169
https://www.valueinhealthjournal.com/article/S1098-3015(21)00386-7/fulltext
Title :
PCN77 Cost-effectiveness analysis of adjuvant FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for resected pancreatic cancer in the United States: based on PRODIGE and APACT trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00386-7&doi=10.1016/j.jval.2021.04.169
First page :
Section Title :
Open access? :
No
Section Order :
10745